Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 57
Filtrar
3.
J Arrhythm ; 39(5): 681-756, 2023 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-37799799

RESUMO

Cardiac physiologic pacing (CPP), encompassing cardiac resynchronization therapy (CRT) and conduction system pacing (CSP), has emerged as a pacing therapy strategy that may mitigate or prevent the development of heart failure (HF) in patients with ventricular dyssynchrony or pacing-induced cardiomyopathy. This clinical practice guideline is intended to provide guidance on indications for CRT for HF therapy and CPP in patients with pacemaker indications or HF, patient selection, pre-procedure evaluation and preparation, implant procedure management, follow-up evaluation and optimization of CPP response, and use in pediatric populations. Gaps in knowledge, pointing to new directions for future research, are also identified.

4.
Heart Rhythm ; 20(9): e17-e91, 2023 09.
Artigo em Inglês | MEDLINE | ID: mdl-37283271

RESUMO

Cardiac physiologic pacing (CPP), encompassing cardiac resynchronization therapy (CRT) and conduction system pacing (CSP), has emerged as a pacing therapy strategy that may mitigate or prevent the development of heart failure (HF) in patients with ventricular dyssynchrony or pacing-induced cardiomyopathy. This clinical practice guideline is intended to provide guidance on indications for CRT for HF therapy and CPP in patients with pacemaker indications or HF, patient selection, pre-procedure evaluation and preparation, implant procedure management, follow-up evaluation and optimization of CPP response, and use in pediatric populations. Gaps in knowledge, pointing to new directions for future research, are also identified.


Assuntos
Terapia de Ressincronização Cardíaca , Insuficiência Cardíaca , Criança , Humanos , Fascículo Atrioventricular , Resultado do Tratamento , Doença do Sistema de Condução Cardíaco , Terapia de Ressincronização Cardíaca/métodos , Insuficiência Cardíaca/terapia , Eletrocardiografia/métodos
12.
Heart Rhythm ; 16(9): e227-e279, 2019 09.
Artigo em Inglês | MEDLINE | ID: mdl-30412777
13.
Heart Rhythm ; 16(9): e128-e226, 2019 09.
Artigo em Inglês | MEDLINE | ID: mdl-30412778
19.
Pacing Clin Electrophysiol ; 37(1): 48-62, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23981048

RESUMO

BACKGROUND: Because as many as 46% of implantable cardioverter defibrillator (ICD) patients experience clinical symptoms of shock anxiety, this randomized controlled study evaluated the efficacy of adapted yoga (vs usual care) in reducing clinical psychosocial risks shown to impact morbidity and mortality in ICD recipients. METHODS: Forty-six participants were randomized to a control group or an 8-week adapted yoga group that followed a standardized protocol with weekly classes and home practice. Medical and psychosocial data were collected at baseline and follow-up, then compared and analyzed. RESULTS: Total shock anxiety decreased for the yoga group and increased for the control group, t(4.43, 36), P < 0.0001, with significant differences between these changes. Similarly, consequential anxiety decreased for the yoga group but increased for the control group t(2.86,36) P = 0.007. Compared to the control, the yoga group had greater overall self-compassion, t(-2.84,37), P = 0.007, and greater mindfulness, t(-2.10,37) P = 0.04, at the end of the study. Exploratory analyses utilizing a linear model (R(2) = 0.98) of observed device-treated ventricular (DTV) events revealed that the expected number of DTV events in the yoga group was significantly lower than in the control group (P < 0.0001). Compared to the control, the yoga group had a 32% lower risk of experiencing device-related firings at end of follow-up. CONCLUSIONS: Our study demonstrated psychosocial benefits from a program of adapted yoga (vs usual care) for ICD recipients. These data support continued research to better understand the role of complementary medicine to address ICD-specific stress in cardiac outcomes.


Assuntos
Ansiedade/etiologia , Ansiedade/terapia , Desfibriladores Implantáveis/efeitos adversos , Desfibriladores Implantáveis/psicologia , Insuficiência Cardíaca/prevenção & controle , Insuficiência Cardíaca/psicologia , Yoga/psicologia , Idoso , Ansiedade/psicologia , Feminino , Insuficiência Cardíaca/complicações , Humanos , Masculino , Resultado do Tratamento
20.
J Interv Card Electrophysiol ; 36(2): 137-44, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23242735

RESUMO

Cardiac implantable electronic devices (CIEDs), despite their proven effectiveness in large clinical trials for a wide range of patients with arrhythmia and heart failure, are frequent targets for criticism regarding cost-efficiency and alleged overuse. Newer indications, such as sinus node dysfunction for pacemakers and primary prevention for implantable cardioverter-defibrillators, increased eligible patient population significantly. This lead to heightened scrutiny from payors and legislative agencies, such as prior authorization and mandatory registry participation. Despite the significant administrative burden, the efficiency of these measures to decrease abuse is not clear. In addition, professional societies, regulatory agencies, and payors may not always agree whether use of a device is appropriate for a given patient. The review focuses on past and current issues related to utilization of CIEDs, which lead to increased regulatory oversight, and the effort of professional societies, payors, and governmental agencies to improve access to these life-saving therapeutical modalities while maintaining a just and cost-efficient healthcare system.


Assuntos
Desfibriladores Implantáveis/economia , Mecanismo de Reembolso , Current Procedural Terminology , Insuficiência Cardíaca/prevenção & controle , Humanos , Medicare/economia , Marca-Passo Artificial , Guias de Prática Clínica como Assunto , Prevenção Primária , Escalas de Valor Relativo , Taquicardia Ventricular/prevenção & controle , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...